Renner W, Köppel H, Brodmann M, Pabst E, Schallmoser K, Toplak H, Wascher T C, Pilger E
Department of Medicine, Karl Franzens University, Graz, Austria.
Thromb Haemost. 2000 Jan;83(1):20-2.
G to A mutations at positions 20210 of the prothrombin gene (F2) and 1691 of the factor V gene (F5) are established risk factors for venous thrombosis. Several factors associated with coagulation and/or fibrinolysis have been associated with arterial occlusive disease, but the role of F2 20210A and F5 1691A for arterial occlusive disease remains unclear.
To investigate if F2 20210A and F5 1691A are associated with peripheral arterial occlusive disease (PAOD).
We analyzed the prevalence of F2 20210A and F5 1691A alleles in 336 patients with documented PAOD at Fontaine stage II-IV and 300 controls without vascular disease. Allele frequencies in patients and controls were 0.013 and 0.022 for F2 20210A, and 0.042 and 0.045 for F5 1691, respectively, both differences being not statistically significant.
Our data suggest that mutations F2 G20210A and F5 G1691A are not associated with PAOD.
凝血酶原基因（F2）第20210位的G到A突变以及因子V基因（F5）第1691位的突变是静脉血栓形成的既定危险因素。一些与凝血和/或纤维蛋白溶解相关的因素已被证实与动脉闭塞性疾病有关，但F2 20210A和F5 1691A在动脉闭塞性疾病中的作用仍不清楚。
研究F2 20210A和F5 1691A是否与外周动脉闭塞性疾病（PAOD）相关。
我们分析了336例记录在案的处于Fontaine II-IV期的PAOD患者以及300例无血管疾病的对照者中F2 20210A和F5 1691A等位基因的流行情况。F2 20210A在患者和对照者中的等位基因频率分别为0.013和0.022，F5 1691A分别为0.042和0.045，两者差异均无统计学意义。
我们的数据表明，F2 G20210A和F5 G1691A突变与PAOD无关。
